Related Experiment Video

Updated: Jul 9, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.5K

Lnc-PTCHD4-AS inhibits gastric cancer through MSH2-MSH6 dimerization and ATM-p53-p21 activation

Jingyun Wang1,2, Yang Mi1,2,3, Xiangdong Sun1,2

  • 1Henan Key Laboratory for Helicobacter pylori and Microbiota and GI Cancer, Marshall Medical Research Center, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.

Aging
|November 28, 2023
PubMed

Insights

A novel long non-coding RNA, PTCHD4-AS, is downregulated in gastric cancer (GC). Upregulating PTCHD4-AS inhibits GC cell proliferation and enhances cisplatin sensitivity by activating the ATM-p53-p21 pathway.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) roles in gastric cancer (GC) remain underexplored.
  • PTCHD4-AS is a conserved lncRNA identified as downregulated in GC.

Purpose of the Study:

  • To investigate the function and mechanism of the novel lncRNA PTCHD4-AS in gastric cancer.
  • To explore PTCHD4-AS's potential as a therapeutic target for GC.

Main Methods:

  • Identification and characterization of PTCHD4-AS in GC cell lines and tissues.
  • Analysis of PTCHD4-AS expression in response to DNA damage agents.
  • Investigation of PTCHD4-AS's role in cell cycle, apoptosis, and drug sensitivity.
  • Molecular mechanism studies involving protein-RNA interactions and pathway analysis.

Main Results:

  • PTCHD4-AS is conserved, downregulated in GC, and transcriptionally induced by DNA damage.
  • PTCHD4-AS upregulation causes G2/M cell cycle arrest and enhances cisplatin-induced apoptosis in GC cells.
  • PTCHD4-AS directly binds to the MSH2-MSH6 dimer, promoting ATM-p53-p21 pathway activation.

Conclusions:

  • PTCHD4-AS inhibits GC cell proliferation and increases sensitivity to cisplatin.
  • The mechanism involves PTCHD4-AS binding to MSH2-MSH6 and activating the ATM-p53-p21 signaling pathway.
  • PTCHD4-AS represents a potential therapeutic target for gastric cancer treatment.
Keywords:
DNA mismatch repair proteinsMSH2-MSH6cisplatingastric cancerlong non-coding RNA PTCHD4-AS

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K